Immune checkpoint: Difference between revisions
Jump to navigation
Jump to search
m Added see also |
|||
| Line 19: | Line 19: | ||
* [[Ipilimumab]] (Yervoy) | * [[Ipilimumab]] (Yervoy) | ||
==See also== | |||
* [[Cell cycle checkpoint]] | * [[Cell cycle checkpoint]] | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 05:32, 13 November 2017
Immune checkpoint inhibitors
Monoclonal antibodies have been developed to target immune checkpoints.
PD-1 inhibitors
These antibodies target the Programmed Cell Death 1 Receptor (PD-1 Receptor). Programmed Cell Death Type I is also known as apoptosis. The PD-1 Receptor is "an inhibitory T-lymphocyte receptor that has specificity for CD274 antigen and Programmed Cell Death 1 Ligand 2 Protein."[1]
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
PD-L1 inhibitors
- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Durvalumab (Imfinzi)
CTLA-4 blockade
The CTLA-4 Antigen is "an inhibitory T cell receptor that is closely related to CD28 antigen. It has specificity for CD80 antigen and CD86 antigen and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing peripheral tolerance."[2]
- Ipilimumab (Yervoy)
See also
References
- ↑ Anonymous (2024), Programmed Cell Death 1 Receptor (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), CTLA-4 Antigen (English). Medical Subject Headings. U.S. National Library of Medicine.